Dual antiplatelet therapy for prevention of recurrent ischemic events

American Journal of Health-System Pharmacy

Volumn 59, Issue 18, 2002, Pages 1723-1735

  Nappi, Jean ^a   Talbert, Robert ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aspirin; Clopidogrel; Combined therapy; Dipyridamole; Ischemia; Mechanism of action; Platelet aggregation inhibitors; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONVALESCENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HEART FAILURE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0037106173     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.18.1723     Document Type: Review

References (99)

1. Incidence and occurrence of total (first-ever and recurrent) stroke
2. Health-related quality of life among long-term survivors of stroke: Results from the Auckland Stroke Study, 1991-1992
3. Current advances in the management of stroke
4. Antithrombotic and thrombolytic therapy for ischemic stroke
5. Antithrombotic agents in coronary artery disease
6. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories
7. Epidemiologic relationship of disease among the different vascular territories
8. Antiplatelet therapy in the prevention of ischemic vascular events: Literature review and evidence-based guidelines for drug selection
9. Atherothrombosis: Mechanisms and clinical therapeutic approaches
10. Multiple mechanisms of thrombosis complicating atherosclerotic plaques
11. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
12. Tirofiban: An investigational platelet glycoprotein IIb/IIIa receptor antagonist
13. Antiplatelet and anti-coagulant therapy in the secondary prevention of ischemic heart disease
14. Platelets in health and disease: Platelet GPIIb-IIIa structure and function: Recent advances in anti-platelet therapy
15. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences
16. Biology of arterial atheroma
17. Atherothrombosis: The role of platelets
18. Pathophysiology of plaque disruption and thrombosis in acute ischemic syndromes
19. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics ractice
20. Clopidogrel for cerebrovascular prevention
21. Prevention of recurrent stroke
22. Atherosclerotic plaque rupture and thrombosis. Evolving concepts
23. Anti-platelet and anticoagulant use after myocardial infarction
24. Aspirin
25. Aspirin and platelets: The anti-platelet action of aspirin and its role in thrombosis treatment and prophylaxis
26. Cyclooxygenases 1 and 2
27. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity
28. Increased prostacyclin production from human veins by dipyridamole: An in vitro and ex vivo study
29. Anti-arrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: Evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias
30. Effects of dipyridamole, nifedipine, verapamil, hydralazine and propranolol on the formation of prostacyclin and thromboxane in a coupled system of platelets and aorta
31. Dipyridamole and aspirin in relation to platelet aggregation and vessel wall prostaglandin generation
32. Antiplatelet therapy in coronary artery disease: Review and update of efficacy studies
33. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
34. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
35. ACC/AHA guidelines for percutaneous coronary interventions (revisions of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty)
36. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of Phase III multicenter randomized trials
37. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
38. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
39. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial
40. A randomized comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes (ACS): Results of the 2nd SYMPHONY trial
41. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
42. Collaborative overview of randomised, trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
43. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke
44. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
45. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
46. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
47. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: Final results
48. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
49. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
50. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials
51. AHA scientific statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association
52. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
53. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
54. Anti-platelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial
55. Ticlopidine versus Aspirin after Myocardial Infarction (STAMI) trial
56. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
57. Benefit of clopidogrel in patients with coronary disease
58. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
59. The Aspirin Myocardial Infarction Study: Final results
60. Aspirin in coronary heart disease
61. The German-Austrian aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction
62. Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: Why aspirin improves ticlopidine antiplatelet activity
63. Development of aspirin resistance in persons with previous ischemic stroke
64. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients
65. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes
66. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
67. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
68. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis
69. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat
70. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
71. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin
72. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy
73. Combination aspirin-clopidogrel therapy in patients with ischemic stroke
74. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction
75. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
76. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
77. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results
78. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): A randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction
79. Clopidogrel and coronary stenting: What is the next question?
80. Management of atherothrombosis with clopidogrel in high-risk patients with recent TIA or ischaemic stroke (MATCH): Rationale and study design
81. Does heart failure confer a hypercoagulable state? Virchow's triad revisited
82. Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin
83. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
84. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
85. The European Stroke Prevention Study (ESPS): Principal endpoints
86. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia
87. The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: A short duration follow-up study
88. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically
89. Thrombotic thrombocytopenic purpura associated with clopidogrel
90. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting
91. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting
92. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting